CD137 Antibody (BBK-2): sc-58947

CD137 Antibody (BBK-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD137 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD137 (BBK-2) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD137 protein, also known as ILA and 4-1BB in mouse, is a member of the tumor necrosis factor receptor family and plays a crucial role in the immune response by delivering a costimulatory signal to T lymphocytes. CD137 is primarily expressed on activated T cells and interacts with an inducible ligand found on B cells, macrophages, and dendritic cells, which is essential for effective antigen presentation and the generation of cytotoxic T cells. Notably, crosslinking of CD137 ligand can induce apoptosis in resting lymphocytes, while CD137 promotes survival of peripheral monocytes by inducing a specific cytokine release profile, mediated by macrophage colony-stimulating factor and, to a lesser extent, granulocyte-macrophage colony-stimulating factor and interleukin-3. Additionally, soluble forms of CD137 have been detected in sera of patients with rheumatoid arthritis, suggesting a potential role in modulating immune responses and providing a negative feedback mechanism.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD137 Antibody (BBK-2) References:

1. Identification of CD137 as a potent monocyte survival factor.  |  Langstein, J. and Schwarz, H. 1999. J Leukoc Biol. 65: 829-33. PMID: 10380906
2. CD137-induced apoptosis is independent of CD95.  |  Michel, J., et al. 1999. Immunology. 98: 42-6. PMID: 10469232
3. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes.  |  Kienzle, G. and von Kempis, J. 2000. Int Immunol. 12: 73-82. PMID: 10607752
4. Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes.  |  Michel, J. and Schwarz, H. 2000. Cytokine. 12: 742-6. PMID: 10843756
5. Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation.  |  Langstein, J., et al. 2000. Biochem Biophys Res Commun. 273: 117-22. PMID: 10873573
6. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.  |  Myers, L., et al. 2006. Int Immunol. 18: 325-33. PMID: 16373363
7. CD137-mediated immunotherapy for allergic asthma.  |  Polte, T., et al. 2006. J Clin Invest. 116: 1025-36. PMID: 16528411
8. Expression of CD137 and CD137 ligand in colorectal cancer patients.  |  Dimberg, J., et al. 2006. Oncol Rep. 15: 1197-200. PMID: 16596186
9. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.  |  McMillin, DW., et al. 2006. Hum Gene Ther. 17: 798-806. PMID: 16942440
10. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.  |  Claus, C., et al. 2023. MAbs. 15: 2167189. PMID: 36727218
11. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.  |  Pichler, AC., et al. 2023. Immunity. 56: 1631-1648.e10. PMID: 37392737
12. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.  |  Mikami, H., et al. 2024. Cancer Immunol Res. 12: 719-730. PMID: 38558120

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD137 Antibody (BBK-2) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-CD137 Antibody (BBK-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD137 Antibody (BBK-2) Specifications

Alternate Product Name: CD137

Product Clone Name: BBK-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD137

Epitope Species: human

Product Reactivity/Detection: CD137

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for CD137 Antibody (BBK-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin